- Home
- IINN vs OTLK Comparison
IINN vs OTLK Comparison
Compare IINN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IINN | OTLK |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 38.7M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IINN | OTLK |
|---|---|---|
| Price | $0.79 | $0.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $3.83 |
| AVG Volume (30 Days) | 189.7K | ★ 12.7M |
| Earning Date | 03-09-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $289,000.00 | ★ $1,413,535.00 |
| Revenue This Year | N/A | $1,578.49 |
| Revenue Next Year | $9,715.95 | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.49 |
| 52 Week High | $1.65 | $3.39 |
Technical Indicators
Market Signals| Indicator | IINN | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 24.53 |
| Support Level | $0.75 | $0.51 |
| Resistance Level | $0.91 | $0.54 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 14.44 | 11.58 |
Price Performance
Historical ComparisonAbout IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.